4.6 Article

Sialylation of CD55 by ST3GAL1 Facilitates Immune Evasion in Cancer

期刊

CANCER IMMUNOLOGY RESEARCH
卷 9, 期 1, 页码 113-122

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-20-0203

关键词

-

资金

  1. Chang Gung Medical Foundation in Taiwan [MOST 103-2321-B-182A-005, MOST 104-2321-B-182A-003, MOST 105-2321-B-182A-001, OMRPG3C0014, MOST 106-3114-B-182A-001, MOST 107-2321-B-182A-005, MOST 108-2321-B-182A-004, MOST 109-2321-B-182A-005, CMRPG3G1531-CMRPG3G1533]
  2. Ministry of Science and Technology

向作者/读者索取更多资源

The altered glycosylations associated with glycosyltransferases can affect the function of glycoproteins and tumor cell behavior. Silencing ST3GAL1 in breast cancer cells results in changes in the O-glycosylation of CD55, increasing sensitivity to immune attacks.
Altered glycosylations, which are associated with expression and activities of glycosyltransferases, can dramatically affect the function of glycoproteins and modify the behavior of tumor cells. ST3GAL1 is a sialyltransferase that adds sialic acid to core 1 glycans, thereby terminating glycan chain extension. In breast carcinomas, overexpression of ST3GAL1 promotes tumorigenesis and correlates with increased tumor grade. In pursuing the role of ST3GAL1 in breast cancer using ST3GAL1-siRNA to knockdown ST3GAL1, we identified CD55 to be one of the potential target proteins of ST3GAL1. CD55 is an important complement regulatory protein, preventing cells from complement-mediated cytotoxicity. CD55 had one N-linked glycosylation site in addition to a Ser/Thr-rich domain, which was expected to be heavily O-glycosylated. Detailed analyses of N- and O-linked oligosaccharides of CD55 released from scramble or ST3GAL1 siRNA-treated breast cancer cells by tandem mass spectrometry revealed that the N-glycan profile was not affected by S'IMAL1 silencing. The O-glycan profile of CD55 demonstrated a shift in abundance to nonsialylated core 1 and monosialylated core 2 at the expense of the disialylated core 2 structure after ST3GAL1 silencing. We also demonstrated that O-linked desialylation of CD55 by ST3GAL1 silencing resulted in increased C3 deposition and complement-mediated lysis of breast cancer cells and enhanced sensitivity to antibody-dependent cell-mediated cytotoxicity. These data demonstrated that ST3GAL1-mediated O-linked sialylation of CD55 acts like an immune checkpoint molecule for cancer cells to evade immune attack and that inhibition of ST3GAL1 is a potential strategy to block CD55-mediated immune evasion.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据